Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population

Subjects

Abstract

Hepatocellular carcinoma (HCC) recurrence is one of the leading causes of death after orthotopic liver transplantation (OLT). The sixth complement component (C6) is a late-acting complement protein that participates in the assembly of the membrane attack complex, which has an indispensable role in innate and acquired immune responses, as well as cancer immune surveillance. However, studies assessing the association between C6 and HCC recurrence after OLT are scarce. This study aimed to evaluate the association of donor and recipient C6 single-nucleotide polymorphisms with the risk for HCC recurrence after OLT. A total of 71 adult patients who underwent primary LT for HCC were enrolled. HCC recurrence was observed in 26 (36.6%) patients. Ten single-nucleotide polymorphisms were genotyped and analyzed in both donor and recipient groups. Patients with the rs9200 heterozygous GA variant presented significantly higher HCC recurrence rates (54.17 vs 27.66%, P=0.028), and lower cumulative tumor-free survival and overall survival (P=0.006 and P=0.013, respectively) compared with those harboring the GG/AA genotype, in multivariate logistic regression and Cox regression analyses. The rs9200 heterozygous GA variant in C6 persisted as a statistically independent prognostic factor (P<0.05) for predicting HCC recurrence after OLT. In conclusion, recipient C6 rs9200 polymorphism is associated with HCC recurrence after OLT, and improves the predictive value of clinical models.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153–156.

    Article  CAS  Google Scholar 

  2. El-Serag HB, Rudolph KL . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576.

    Article  CAS  Google Scholar 

  3. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 187–196.

    Article  Google Scholar 

  4. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143: 182–188.

    Article  Google Scholar 

  5. Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008; 15: 1375–1382.

    Article  Google Scholar 

  6. Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007; 13: 543–551.

    Article  Google Scholar 

  7. Tsoulfas G, Kawai T, Elias N, Ko SC, Agorastou P, Cosimi AB et al. Long-term experience with liver transplantation for hepatocellular carcinoma. J Gastroenterol 2011; 46: 249–256.

    Article  Google Scholar 

  8. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35–43.

    Article  Google Scholar 

  9. Chan DL, Alzahrani NA, Morris DL, Chua TC . Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 31–41.

    Article  Google Scholar 

  10. Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology 2015; 61: 895–904.

    Article  CAS  Google Scholar 

  11. Yan J, Tan C, Gu F, Jiang J, Xu M, Huang X et al. Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase. Liver Transpl 2013; 19: 507–520.

    Article  Google Scholar 

  12. Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N et al. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford) 2013; 15: 504–510.

    Article  Google Scholar 

  13. Wang P, Song W, Li H, Wang C, Shi B, Guo W et al. Association between donor and recipient smoothened gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population. Tumour Biol 2015; 36: 7807–7815.

    Article  CAS  Google Scholar 

  14. Xu X, Ling Q, Wang J, Xie H, Wei X, Lu D et al. Donor miR-196a-2 polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation in a Han Chinese population. Int J Cancer 2015; 138: 620–629.

    Article  Google Scholar 

  15. Nicholson-Weller A, Halperin JA . Membrane signaling by complement C5b-9, the membrane attack complex. Immunol Res 1993; 12: 244–257.

    Article  CAS  Google Scholar 

  16. Wang C, Bozza PT, Barbashov SF, Sauty A, Nicholson-Weller A . In vitro and in vivo responses of murine granulocytes to human complement-derived, haemolytically inactive C5b67 (iC5b67). Clin Exp Immunol 1999; 117: 261–268.

    Article  CAS  Google Scholar 

  17. Wurzner R, Orren A, Lachmann PJ . Inherited deficiencies of the terminal components of human complement. Immunodefic Rev 1992; 3: 123–147.

    CAS  PubMed  Google Scholar 

  18. Ramaglia V, King RH, Nourallah M, Wolterman R, de Jonge R, Ramkema M et al. The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J Neurosci 2007; 27: 7663–7672.

    Article  CAS  Google Scholar 

  19. Oka R, Sasagawa T, Ninomiya I, Miwa K, Tanii H, Saijoh K . Reduction in the local expression of complement component 6 (C6) and 7 (C7) mRNAs in oesophageal carcinoma. Eur J Cancer 2001; 37: 1158–1165.

    Article  CAS  Google Scholar 

  20. Piao C, Cai L, Qiu S, Jia L, Song W, Du J . Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-mediated inflammatory cell infiltration. J Biol Chem 2015; 290: 10667–10676.

    Article  CAS  Google Scholar 

  21. Narayanasamy A, Ahn JM, Sung HJ, Kong DH, Ha KS, Lee SY et al. Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC). J Proteomics 2011; 74: 2948–2958.

    Article  CAS  Google Scholar 

  22. Gabriel S, Ziaugra L, Tabbaa D . SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet 2009; Chapter 2: Unit 2.12.

    PubMed  Google Scholar 

  23. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699.

    Article  CAS  Google Scholar 

  24. Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM . Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett 2005; 97: 171–179.

    Article  CAS  Google Scholar 

  25. Pio R, Corrales L, Lambris JD . The role of complement in tumor growth. Adv Exp Med Biol 2014; 772: 229–262.

    Article  CAS  Google Scholar 

  26. Cragg MS, Glennie MJ . Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738–2743.

    Article  CAS  Google Scholar 

  27. Kolev M, Towner L, Donev R . Complement in cancer and cancer immunotherapy. Arch Immunol Ther Exp (Warsz) 2011; 59: 407–419.

    Article  CAS  Google Scholar 

  28. Jurianz K, Ziegler S, Garcia-Schüler H, Kraus S, Bohana-Kashtan O, Fishelson Z et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999; 36: 929–939.

    Article  CAS  Google Scholar 

  29. Halme J, Sachse M, Vogel H, Giese T, Klar E, Kirschfink M . Primary human hepatocytes are protected against complement by multiple regulators. Mol Immunol 2009; 46: 2284–2289.

    Article  CAS  Google Scholar 

  30. Zhang S, Shan C, Cui W, You X, Du Y, Kong G et al. Hepatitis B virus X protein protects hepatoma and hepatic cells from complement-dependent cytotoxicity by up-regulation of CD46. FEBS Lett 2013; 587: 645–651.

    Article  CAS  Google Scholar 

  31. Miura I, Graziano SL, Cheng JQ, Doyle LA, Testa JR . Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. Cancer Res 1992; 52: 1322–1328.

    CAS  PubMed  Google Scholar 

  32. Van den Berghe H, Le Beau M, Bernheim A . Fourth international workshop on chromosomes in leukemia 1982: deletion of 5q. Cancer Genet Cytogenet 1984; 11: 296–299.

    Article  CAS  Google Scholar 

  33. Wieland I, Bohm M . Frequent allelic deletion at a novel locus on chromosome 5 in human lung cancer. Cancer Res 1994; 54: 1772–1774.

    CAS  PubMed  Google Scholar 

  34. DiScipio RG, Hugli TE . The molecular architecture of human complement component C6. J Biol Chem 1989; 264: 16197–16206.

    CAS  PubMed  Google Scholar 

  35. Westra D, Kurvers RA, van den Heuvel LP, Würzner R, Hoppenreijs EP, van der Flier M et al. Compound heterozygous mutations in the C6 gene of a child with recurrent infections. Mol Immunol 2014; 58: 201–205.

    Article  CAS  Google Scholar 

  36. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 2012; 40: 1733–1747.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was partly supported by a grant from the National Natural Science Foundation of China (81370579) and the Science and Technology Commission of Shanghai Municipality, China (134119a6300).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Z Wang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Z., Liao, J., Wu, S. et al. Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population. Cancer Gene Ther 23, 157–161 (2016). https://doi.org/10.1038/cgt.2016.7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2016.7

This article is cited by

Search

Quick links